p53 switches off pluripotency on differentiation.
TongXiang LinYi LinPublished in: Stem cell research & therapy (2017)
The role of p53 as "a guardian of the genome" has been well established in somatic cells. However, its role in pluripotent stem cells remains much more elusive. Here, we discuss research progress in understanding the role of p53 in pluripotent stem cells and in pluripotent stem cell-like cancer stem cells. The p53 protein, which plays a key role in embryonic stem cells, was first discovered in 2005. Landmark studies of p53-related reprogramming elucidated this protein's importance in induced pluripotent stem cells in 2009. The p53-related safety concerns in pluripotent stem cells have been raised in stem cell-based therapy although the use of iPSCs in therapeutic application is promising. Because cancer stem cells have profiles similar to those of pluripotent stem cells, we also describe potential strategies for studies in cancer stem cells and cancer treatments. The new discoveries of p53 family proteins in pluripotent stem cells have made possible stable progress in stem cell transplantation efficiency and safety, as well as treatment strategies targeting cancer stem cells based on pluripotent stem cell technology.
Keyphrases
- pluripotent stem cells
- cancer stem cells
- stem cells
- stem cell transplantation
- embryonic stem cells
- induced pluripotent stem cells
- high dose
- induced apoptosis
- cell therapy
- papillary thyroid
- cell cycle arrest
- cell death
- binding protein
- low dose
- climate change
- drug delivery
- genome wide
- squamous cell
- risk assessment
- squamous cell carcinoma
- cancer therapy
- endoplasmic reticulum stress
- copy number
- mesenchymal stem cells
- smoking cessation